西妥昔单抗对难治性卵巢癌初步效果(附1例报告)

EFFECT OF CETUXIMAB ON REFRACTORY OVARIAN CARCINOMA:REPORT OF ONE CASE

目的探讨西妥昔单抗(C225)治疗难治性卵巢癌的有效性及安全性。方法 1例晚期卵巢癌病人,在紫杉类、顺铂多药耐药后,应用C225联合奥沙利铂、足叶乙甙化疗1周期,随后改用C225单药治疗2周期,评价C225联合化疗及单药应用的近期疗效及副作用。结果 C225联合化疗治疗1周期后肿瘤迅速消退、脱落以致形成结肠-阴道瘘,主要副作用为Ⅲ度骨髓抑制和低热;C225单药治疗2周期,肿瘤呈持续进展,主要副作用为低热。结论 C225联合化疗治疗难治性卵巢癌可能是有效和安全的,单药C225未显示治疗优势。

Objective To evaluate the therapeutic effect and safety of cetuximab（C225） on refractory ovarian cancer（OC）. Methods An OC patient with multidrug resistance（yews and cis-platinum） was treated with combined chemotherapy of C225,oxaliplatin and Etoposide for one cycle,then followed by two cycles of C225 alone.The short-term effect and toxicity reaction was assessed. Results After one cycle of the combined chemotherapy,the tumor subsided and disappeared quickly,resulting in colovaginal fistula.The major toxic and side reactions were Ⅲ degree bone marrow depression and low-grade fever.After therapy with C225 alone for two cycles,the tumor developed continuously,low-grade fever being the main adverse effect. ConclusionC225 combined chemotherapy seems to be effective and safe for refractory ovarian cancer,while C225 alone does not show its superiority.